四川医学
四川醫學
사천의학
SICHUAN MEDICAL JOURNAL
2014年
4期
435-437
,共3页
刘恒伟%朱焕玲%孟文彤%刘霆
劉恆偉%硃煥玲%孟文彤%劉霆
류항위%주환령%맹문동%류정
半定量RT-PCR%慢性粒细胞白血病%伊马替尼%hOCT1
半定量RT-PCR%慢性粒細胞白血病%伊馬替尼%hOCT1
반정량RT-PCR%만성립세포백혈병%이마체니%hOCT1
semi-quantity RT-PCR,chronic myelogenous leukemia%imatinib%hOCT1
目的：动态检测慢性粒细胞白血病( CML)患者服用伊马替尼缓解或耐药前后的hOCT1基因表达变化,初步探讨hOCT1基因表达变化与疾病缓解或伊马替尼耐药相关性。方法采用半定量RT-PCR方法对服用伊马替尼CML患者缓解或耐药前后的2个不同时点的9对(18份)标本进行了hOCT 1基因mRNA水平检测,并对半定量RT-PCR结果结合临床表现、实验室检查和细胞遗传学结果,分析其水平变化和与疾病缓解或伊马替尼耐药相关性。结果慢性期CML患者5例,第一和二次检测hOCT1相对表达量为(0．4246±0．2067)、(0．4858±0．1943),P=0．705,差异无统计学意义。对进展期CML患者4例前后两次hOCT1相对表达量比较,有3例患者hOCT1相对表达量降低,1例患者hOCT1相对表达量升高。结论半定量RT-PCR方法方便简单,可以用于检测服用伊马替尼的CML患者hOCT1基因表达及变化,或许有可能用于慢性粒细胞白血病伊马替尼反应或耐药的检测及其机制的研究。
目的：動態檢測慢性粒細胞白血病( CML)患者服用伊馬替尼緩解或耐藥前後的hOCT1基因錶達變化,初步探討hOCT1基因錶達變化與疾病緩解或伊馬替尼耐藥相關性。方法採用半定量RT-PCR方法對服用伊馬替尼CML患者緩解或耐藥前後的2箇不同時點的9對(18份)標本進行瞭hOCT 1基因mRNA水平檢測,併對半定量RT-PCR結果結閤臨床錶現、實驗室檢查和細胞遺傳學結果,分析其水平變化和與疾病緩解或伊馬替尼耐藥相關性。結果慢性期CML患者5例,第一和二次檢測hOCT1相對錶達量為(0．4246±0．2067)、(0．4858±0．1943),P=0．705,差異無統計學意義。對進展期CML患者4例前後兩次hOCT1相對錶達量比較,有3例患者hOCT1相對錶達量降低,1例患者hOCT1相對錶達量升高。結論半定量RT-PCR方法方便簡單,可以用于檢測服用伊馬替尼的CML患者hOCT1基因錶達及變化,或許有可能用于慢性粒細胞白血病伊馬替尼反應或耐藥的檢測及其機製的研究。
목적：동태검측만성립세포백혈병( CML)환자복용이마체니완해혹내약전후적hOCT1기인표체변화,초보탐토hOCT1기인표체변화여질병완해혹이마체니내약상관성。방법채용반정량RT-PCR방법대복용이마체니CML환자완해혹내약전후적2개불동시점적9대(18빈)표본진행료hOCT 1기인mRNA수평검측,병대반정량RT-PCR결과결합림상표현、실험실검사화세포유전학결과,분석기수평변화화여질병완해혹이마체니내약상관성。결과만성기CML환자5례,제일화이차검측hOCT1상대표체량위(0．4246±0．2067)、(0．4858±0．1943),P=0．705,차이무통계학의의。대진전기CML환자4례전후량차hOCT1상대표체량비교,유3례환자hOCT1상대표체량강저,1례환자hOCT1상대표체량승고。결론반정량RT-PCR방법방편간단,가이용우검측복용이마체니적CML환자hOCT1기인표체급변화,혹허유가능용우만성립세포백혈병이마체니반응혹내약적검측급기궤제적연구。
Objective To monitor hOCT1 gene expression in CML patients treated with imatinb mesylate and observe the correlation between hOCT1 gene variation and BCR-ABL molecular response conditions. Methods By semi-quantity RT-PCR (SQ-PCR), hOCT1 gene mRNA levels were detected from 9 pairs of (18) samples on two different time points around the course of response or drug resistance to imatinib in patients with chronic myelogenous leukemia respectively. The results of their SQ-PCRs were compared with clinical presentations, laboratory detections and cytogenetic findings thereof, to get some information on the correlation between changes of hOCT1 gene levels and disease response or resistance to imatinib. Results The relative expression levels of hOCT1 gene were(0. 4246 ± 0. 2067),(0. 4858 ± 0. 1943), with P=0. 705 and without statistical significance in both tests 1 and 2 in 5 patients with chronic myelogenous leukemia in chronic phase, respectively. The relative expression levels of hOCT1 gene between two tests increased in 3 and decreased in 1 of 4 patients with advanced stage of chronic myelogenous leukemia respectively. Conclusion This study established a relatively simple and useful method to detect hOCT1 gene expression that prob-ably can be used in the study on imatinib resistance.
